Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of AZN revenue | Skew |
|---|---|---|---|
| NKTRNektar Therapeutics | 17.00% | 0.01% | 1,394× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On October 5, 2021, AstraZeneca acquired Caelum Biosciences, Inc. ("Caelum"), a former subsidiary of Fortress for an upfront payment of approximately $135 million paid to Caelum shareholders, of which approximately $56.9 million was paid to Fortress.”
FILING10-K0001104659-26-037874cik 0001429260disclosed by FBIO
“Our WAINUA joint development revenue in 2024 included a $30 million milestone payment from AstraZeneca that we earned when the Medicines and Healthcare products Regulatory Agency, or MHRA, approved WAINUA for ATTRv-PN in the UK as WAINZUA.”
FILING10-K0000874015-26-000115cik 0000874015disclosed by IONS
“Under the terms of the amended and restated agreement, we transferred all manufacturing responsibilities in China (including Hong Kong and Macau) to AstraZeneca, and we were entitled to receive non-contingent payments totaling $35.0 million in three installments through 2024, with the final installment collected during the first quarter of 2024.”
FILING10-K0001104659-26-020489cik 0001446847disclosed by IRWD
“In 2020, we entered into a Master Supply Agreement with AstraZeneca under the AstraZeneca U.S./RoW Agreement (the "AstraZeneca Master Supply Agreement") to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from Kyntra Bio in support of commercial supplies.”
FILING10-K0001193125-26-108346cik 0000921299disclosed by KYNB
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$9M relationship1,394× more of NKTR’s book than AZN’s
basisNKTR fy2025 · closed 2025-12 $55MAZN fy2025 · closed 2025-12 $77.0B
“Under the MSA, we agreed, on a non-exclusive basis, to provide AstraZeneca with certain of our products and services, including licensed data, sequencing, clinical trial matching, organoid modeling services, algorithm development, and others.”
FILING10-K0000950170-25-025603cik 0001717115disclosed by TEM
“Construction of the Tarzana facility was subsequently completed and in 2024 the facility was leased to AstraZeneca Pharmaceuticals LP, or Tenant.”
FILING10-K0001789769-26-000019cik 0001789769disclosed by TIL
“Our current ZYNLONTA pipeline utilizes our highly potent pyrrolobenzodiazepine ("PBD") dimer technology (under license from AstraZeneca).”
FILING10-K0001628280-26-016491cik 0001771910disclosed by ADCT
“In October 2016, we entered into the AZ License Agreement, pursuant to which AstraZeneca granted us exclusive global rights for the purpose of developing and commercializing AZD7986 (which we renamed brensocatib).”
FILING10-K0001104506-26-000009cik 0001104506disclosed by INSM
“Pursuant to the terms of our license agreement with AstraZeneca for ALXN1840, we obtained the intellectual property portfolio for ALXN1840, including exclusive license and prosecution of over 86 patent applications granted, published, or pending in over 30 countries worldwide.”
FILING10-K0001437749-26-010025cik 0001645469disclosed by MNPR
“For example, in late 2025, AstraZeneca terminated its phase 3 TROPION-Lung12 trial due to low enrollment, for which our methylation technology was used as a potential companion diagnostic for enrolling participants.”
FILING10-K0001628280-26-017319cik 0001699031disclosed by GRAL
“License and collaboration agreement with AstraZeneca On December 21, 2011, the Group and AstraZeneca AB (publ) ("AZ") entered into a global licensing, co-development, and commercialization agreement for Orpathys ("AZ Agreement"), also known as savolitinib, a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer.”
FILING20-F0001104659-26-023822cik 0001648257disclosed by HCM
“In July 2018, we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications.”
FILING10-K0001787306-26-000018cik 0001787306disclosed by ARQT
“We also have clinical collaboration agreements with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1b/3 study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC.”
FILING10-K0001724521-26-000009cik 0001724521disclosed by RCUS
“Collaboration Agreement with AstraZeneca In March 2020, we entered into a collaboration agreement with AstraZeneca to discover, develop and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases.”
FILING10-K0001193125-26-092591cik 0001479615disclosed by SLN
“We also assumed the AZD7325 license agreement between Baergic and AZ.”
FILING10-K0001193125-26-064267cik 0001579428disclosed by AXSM
“Upon entering into the Original Agreements, we made a payment of $3.0 million and issued 490,798 ordinary shares (equivalent to 98,159 ADSs) to AstraZeneca, for an aggregate upfront payment equal to $5.0 million.”
FILING10-K0001193125-26-115226cik 0001719714disclosed by MREO
“Co-development and commercialization agreement with AstraZeneca signed in 2015 for the product Monalizumab and a multi-term agreement signed in 2018 and subsequent amendment signed in 2020 granting the entirety of the oncology rights to Monalizumab.”
FILING20-F0001598599-26-000005cik 0001598599disclosed by IPHA
“Pursuant to the Joint Research and Collaboration Agreement with AZ Ireland dated November 1, 2023 (the "AZ JRCA"), 25 genetic targets have been exclusively reserved for AZ Ireland, from which up to 10 candidate products could be explored for develo”
FILING20-F0001193125-26-116428cik 0001627281disclosed by CLLS
“We have also established collaborations and other relationships with leading biotechnology and pharmaceutical companies around the world, including a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer”
FILING20-F0001213900-26-049412cik 0002023311disclosed by AAPG
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 161.90 · gapped above the open, then crossed back over prior close. High/low 163.81 at 1:00 pm ET, 161.27 at 9:30 am ET.
Astrazeneca PLC
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Astrazeneca PLC has 12 disclosed suppliers and 8 disclosed customers. Each one is named in an SEC filing, either Astrazeneca PLC’s own annual report or the counterparty’s, and carries the sentence that discloses it.
AZN (Astrazeneca PLC) has 12 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CLLS −12.02%, in industrials & materials.